Crisugabalin

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

Crisugabalin (HSK16149) is a novel GABA analog in development for the treatment of chronic pain. It has a wider therapeutic index than pregabalin, which has a similar mechanism of action. In China, it was approved in May 2024 for the treatment of diabetic peripheral neuropathy with neuropathic pain and approved in July 2024 for the treatment of postherpetic neuralgia.

In the United States, it is in Phase III trials as of 2023. The drug can be administered with or without food.

Crisugabalin (HSK16149) is a novel GABA analog in development for the treatment of chronic pain. It has a wider therapeutic index than pregabalin, which has a similar mechanism of action. In China, it was approved in May 2024 for the treatment of diabetic peripheral neuropathy with neuropathic pain and approved in July 2024 for the treatment of postherpetic neuralgia.

In the United States, it is in Phase III trials as of 2023. The drug can be administered with or without food.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1377083067 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

2 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.